Biogen Inc. Common Stock
BIIB Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Recent trades of BIIB by members of U.S. Congress
BIIB Stock Insider Trading Activity
Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
BIIB Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
BIIB Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in BIIB holdings by institutional investors
Quarterly net insider trading by BIIB's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Backtest Start Date
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Subscribe to Quiver Premium for insider trading alerts
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$990,000 Oct 20, 2025 Issue: Pharmacy Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Trade (domestic/foreign)
-
$1,380,000 Jul 20, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Manufacturing Trade (domestic/foreign)
-
$1,020,000 Apr 21, 2025 Issue: Medicare/Medicaid Pharmacy Manufacturing Trade (domestic/foreign) Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues
-
$700,000 Jan 20, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Manufacturing
-
$710,000 Oct 19, 2024 Issue: Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$1,670,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$1,060,000 Apr 22, 2024 Issue: Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$830,000 Feb 13, 2024 Issue: Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$940,000 Jan 21, 2024 Issue: Transportation Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$1,090,000 Oct 19, 2023 Issue: Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$900,000 Jan 20, 2023 Issue: Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$940,000 Nov 08, 2022 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$900,000 Oct 20, 2022 Issue: Trade (domestic/foreign) Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$1,060,000 Apr 19, 2022 Issue: Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$670,000 Jan 20, 2022 Issue: None
-
$910,000 Oct 19, 2021 Issue: None
-
$980,000 Jul 19, 2021 Issue: None
-
$1,570,000 Apr 20, 2021 Issue: None
-
$890,000 Jan 21, 2021 Issue: None
-
$1,150,000 Oct 19, 2020 Issue: None
-
$760,000 Jul 20, 2020 Issue: None
-
$1,090,000 Apr 20, 2020 Issue: None
-
$266,680 Jan 22, 2020 Issue: None
-
$560,000 Oct 21, 2019 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$280,000 Jul 22, 2019 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid
-
$810,000 Apr 22, 2019 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Trade (domestic/foreign)
-
$790,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$810,000 Oct 22, 2018 Issue: Taxation/Internal Revenue Code Trade (domestic/foreign) Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$890,000 Jul 18, 2018 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark Health Issues
-
$730,000 Apr 19, 2018 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Health Issues
-
$590,000 Jan 18, 2018 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$640,000 Oct 17, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$710,000 Jul 17, 2017 Issue: Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid
-
$740,000 Apr 18, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$630,000 Jan 18, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$710,000 Oct 19, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$730,000 Jul 19, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$620,000 Apr 20, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$540,000 Jan 19, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$570,000 Oct 19, 2015 Issue: Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Medicare/Medicaid Taxation/Internal Revenue Code
-
$580,000 Jul 20, 2015 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$540,000 Apr 20, 2015 Issue: Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid
-
$430,000 Jan 16, 2015 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
-
$460,000 Oct 19, 2014 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$405,000 Jul 21, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
-
$405,000 Apr 18, 2014 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$395,000 Jan 16, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
-
$395,000 Oct 17, 2013 Issue: Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid
-
$435,000 Jul 22, 2013 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$400,000 Apr 22, 2013 Issue: Health Issues Trade (domestic/foreign) Medicare/Medicaid Taxation/Internal Revenue Code
-
$360,000 Jan 22, 2013 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
-
$415,000 Oct 19, 2012 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$440,000 Jul 18, 2012 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid Trade (domestic/foreign)
-
$445,000 Apr 19, 2012 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$520,000 Jan 18, 2012 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$480,000 Oct 20, 2011 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$390,000 Jul 20, 2011 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$420,000 Apr 18, 2011 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid
-
$335,000 Jan 20, 2011 Issue: Medicare/Medicaid Copyright/Patent/Trademark Health Issues Taxation/Internal Revenue Code
-
$365,000 Oct 19, 2010 Issue: Health Issues Copyright/Patent/Trademark Medicare/Medicaid Taxation/Internal Revenue Code
-
$240,000 Jul 20, 2010 Issue: Copyright/Patent/Trademark Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$290,000 Apr 19, 2010 Issue: Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Medicare/Medicaid
-
$290,000 Jan 19, 2010 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
-
$350,000 Oct 19, 2009 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid
-
$300,000 Jul 28, 2009 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
-
$290,000 Apr 20, 2009 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid
-
$170,000 Jan 16, 2009 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$180,000 Oct 16, 2008 Issue: Medicare/Medicaid Copyright/Patent/Trademark Health Issues
-
$180,000 Oct 16, 2008 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$200,000 Apr 18, 2008 Issue: Health Issues Copyright/Patent/Trademark Medicare/Medicaid
-
$620,000 Feb 13, 2008 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid
-
$620,000 Aug 13, 2007 Issue: Health Issues Copyright/Patent/Trademark
-
$281,000 Feb 14, 2007 Issue: Health Issues Medicare/Medicaid
-
$286,000 Aug 11, 2006 Issue: Medicare/Medicaid Pharmacy Health Issues
-
$380,000 Feb 14, 2006 Issue: Medicare/Medicaid
-
$510,000 Oct 27, 2005 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Budget/Appropriations
-
$430,000 Sep 06, 2005 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$370,000 Jun 21, 2004 Issue: Medicare/Medicaid Health Issues
-
$420,000 Jun 21, 2004 Issue: None
-
$60,000 Oct 22, 2003 Issue: Medicare/Medicaid
-
$50,000 Aug 25, 2003 Issue: Medicare/Medicaid
-
$60,000 Aug 13, 2003 Issue: Health Issues Medicare/Medicaid
-
$80,000 Aug 04, 2003 Issue: Retirement Health Issues Medicare/Medicaid
-
$60,000 Aug 01, 2003 Issue: None
-
$66,490 Jul 17, 2003 Issue: Health Issues
-
$30,000 Jun 11, 2003 Issue: None
-
$44,569 Mar 14, 2003 Issue: Health Issues
-
$20,000 Feb 25, 2003 Issue: Budget/Appropriations
-
$60,000 Feb 24, 2003 Issue: Medicare/Medicaid
-
$60,000 Feb 14, 2003 Issue: Health Issues Medicare/Medicaid
-
$100,000 Feb 14, 2003 Issue: Retirement Health Issues Medicare/Medicaid
-
$20,000 Feb 06, 2003 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid
-
$40,000 Feb 04, 2003 Issue: Budget/Appropriations
-
$60,000 Aug 19, 2002 Issue: Budget/Appropriations
-
$100,000 Aug 19, 2002 Issue: Medicare/Medicaid Insurance
-
$60,000 Aug 14, 2002 Issue: Health Issues
-
$60,000 Aug 14, 2002 Issue: Medicare/Medicaid
-
$60,000 Aug 13, 2002 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$80,000 Aug 13, 2002 Issue: Retirement Health Issues Medicare/Medicaid
-
$60,000 Mar 12, 2002 Issue: Medicare/Medicaid Pharmacy
BIIB Estimated quarterly lobbying spending
BIIB Revenue by Segment or Geography
By Segment
By Geography
BIIB Income Statement
BIIB Balance Sheet
BIIB Cash Flow
U.S. Patents
New BIIB patent grants
-
Patent Title: Cytoprotective agent Jan. 03, 2023
-
Patent Title: Hydrophobic interaction protein chromatography under no-salt conditions Jun. 12, 2018
-
Patent Title: Control of protein glycosylation by culture medium supplementation and cell culture process parameters Apr. 17, 2018
-
Patent Title: Compounds that are s1p modulating agents and/or atx modulating agents Apr. 17, 2018
-
Patent Title: Pyrimidinyl tyrosine kinase inhibitors Apr. 17, 2018
-
Patent Title: Compositions and methods for modulation of smn2 splicing in a subject Mar. 27, 2018
-
Patent Title: Anti-blood dendritic cell antigen 2 antibodies and uses thereof Feb. 27, 2018
-
Patent Title: Method for the treatment of inflammatory disorders Feb. 27, 2018
-
Patent Title: S1p and/or atx modulating agents Dec. 26, 2017
-
Patent Title: Bicyclic aryl sphingosine 1-phosphate analogs Nov. 28, 2017
-
Patent Title: Biaryl inhibitors of bruton's tyrosine kinase Nov. 07, 2017
-
Patent Title: S1p modulating agents Nov. 07, 2017
-
Patent Title: Lingo-2 antagonists for treatment of conditions involving motor neurons Oct. 24, 2017
-
Patent Title: Methods of preventing and removing trisulfide bonds Oct. 17, 2017
-
Patent Title: Treating neurological disorders Oct. 03, 2017
-
Patent Title: S1p and/or atx modulating agents Sep. 26, 2017
-
Patent Title: S1p modulating agents Sep. 19, 2017
-
Patent Title: Display screen with graphical user interface Sep. 12, 2017
-
Patent Title: Display screen with a graphical user interface Aug. 29, 2017
-
Patent Title: Anti-α Aug. 29, 2017
-
Patent Title: Compositions comprising antibodies to lingo or fragments thereof Aug. 29, 2017
-
Patent Title: Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto Aug. 22, 2017
-
Patent Title: Method of treating lupus nephritis Aug. 15, 2017
-
Patent Title: Anti-vla-4 related assays Aug. 08, 2017
-
Patent Title: Compositions and methods for modulation of smn2 splicing in a subject Aug. 01, 2017
-
Patent Title: Methods and products for evaluating an immune response to a therapeutic protein Jul. 18, 2017
-
Patent Title: Heterobicyclic sphingosine 1-phosphate analogs Jul. 18, 2017
-
Patent Title: Methods for the detection of jc polyoma virus Jul. 04, 2017
-
Patent Title: Enhancement of transport of therapeutic molecules across the blood brain barrier Jun. 13, 2017
-
Patent Title: Methods of treating autoimmune diseases using a b-cell maturation antigen (bcma) May. 16, 2017
-
Patent Title: Antibodies to vla-1 May. 09, 2017
-
Patent Title: Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases Apr. 11, 2017
-
Patent Title: Human anti-tau antibodies Mar. 21, 2017
-
Patent Title: Display screen with graphical user interface Mar. 14, 2017
-
Patent Title: Display screen with graphical user interface Mar. 14, 2017
-
Patent Title: Trapping reagents for reactive metabolites screening Feb. 28, 2017
-
Patent Title: Bicyclic aryl sphingosine 1-phosphate analogs Feb. 21, 2017
-
Patent Title: Jcv neutralizing antibodies Feb. 14, 2017
-
Patent Title: Jcv neutralizing antibodies Feb. 14, 2017
-
Patent Title: Methods of preventing and removing trisulfide bonds Feb. 07, 2017
-
Patent Title: Atx modulating agents Jan. 31, 2017
-
Patent Title: Compounds that are s1p modulating agents and/or atx modulating agents Jan. 24, 2017
-
Patent Title: Baff, inhibitors thereof and their use in the modulation of b-cell response and treatment of autoimmune disorders Jan. 17, 2017
-
Patent Title: Methods of treating inflammatory disorders using high concentration natalizumab compositions Jan. 03, 2017
-
Patent Title: Atx modulating agents Dec. 20, 2016
-
Patent Title: Stable liquid interferon beta formulations Dec. 20, 2016
-
Patent Title: Display screen with graphical user interface Dec. 06, 2016
-
Patent Title: Spectroscopic analysis of nutrient materials for use in a cell culture process Nov. 29, 2016
-
Patent Title: Syringe Mar. 15, 2016
-
Patent Title: Package Oct. 27, 2015
Government Contracts
Federal grants, loans, and purchases
- $43,477 2024-11-13 00:00:00 Agency: Department of Veterans Affairs
- $21,738 2024-09-04 00:00:00 Agency: Department of Veterans Affairs
- $32,607 2024-07-17 00:00:00 Agency: Department of Veterans Affairs
- $21,738 2024-07-02 00:00:00 Agency: Department of Veterans Affairs
- $21,738 2024-05-16 00:00:00 Agency: Department of Veterans Affairs
- $10,869 2024-05-01 00:00:00 Agency: Department of Veterans Affairs
- $43,477 2024-04-24 00:00:00 Agency: Department of Veterans Affairs
- $10,869 2024-03-13 00:00:00 Agency: Department of Veterans Affairs
- $0 2023-11-02 00:00:00 Agency: Department of Veterans Affairs
- $0 2023-10-23 00:00:00 Agency: Department of Veterans Affairs
Government Contracts
Estimated quarterly amount awarded to BIIB from public contracts
BIIB News
Recent insights relating to BIIB
CNBC Recommendations
Recent picks made for BIIB stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in BIIB
BIIB Analyst Ratings
BIIB Stock Forecasts
...
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
BIIB Analyst Forecasts
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
Frequently Asked Questions
- Is $BIIB stock a Buy, Sell, or Hold?
- What is the price target for $BIIB stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
BIIB Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
Frequently Asked Questions
- Who owns $BIIB stock?
- Who owns the most shares of $BIIB stock?
- What funds own $BIIB stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
BIIB Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view BIIB Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
About BIIB
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
- Address Cambridge, MA
- Market Cap 25.7 billion
- Employees 7,605
- Industrial Classification Biological Products, (No Disgnostic Substances)